MiddleBrook Pharmaceuticals, Inc. (Nasdaq:MBRK) today announced that on
May 29, 2009, it granted options to purchase a total of 3,600 shares of
MiddleBrook's common stock to two (2) new employees as a material
inducement for them to join MiddleBrook. The options were granted
pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under
MiddleBrook's New Hire Stock Incentive Plan, which was approved by
MiddleBrook's Board of Directors on Sept. 26, 2008. The options have a
per share exercise price equal to the closing price of MiddleBrook's
common stock on the NASDAQ Global Market on the business day immediately
preceding the grant date, a ten-year term and vesting over four years,
with 25 percent of the options vesting one year from the grant date and
1/48th of the options vesting monthly thereafter. The options have a
grant date of May 29, 2009.
About MiddleBrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical
company focused on developing and commercializing anti-infective
products that fulfill unmet medical needs. We have developed a
proprietary delivery technology called PULSYS, which enables the
pulsatile delivery, or delivery in rapid bursts, of certain drugs. We
are currently developing a portfolio of anti-infective PULSYS products.
Our near-term corporate strategy is to improve dosing regimens and/or
reduce frequency of dosing which we believe will result in improved
patient dosing convenience and compliance for antibiotics that have been
used and trusted by physicians and patients for decades. MiddleBrook
currently markets KEFLEX, the immediate-release brand of cephalexin, and
MOXATAG – the first and only FDA-approved once-daily amoxicillin. For
more information about MiddleBrook, please visit www.middlebrookpharma.com.
MiddleBrook Pharmaceuticals, Inc.
Investor Relations/Media Contact:
Faith
Pomeroy-Ward: 817-837-1208
